Polatuzumab vedotin

Polatuzumab vedotin
Monoclonal antibody
Type	Whole antibody
Source	Humanized (from mouse)
Target	CD79B
Clinical data
Trade names	Polivy
Other names	DCDS4501A, RG7596, polatuzumab vedotin-piiq
AHFS/Drugs.com	Monograph
MedlinePlus	a619039
License data	EU EMA: by INN; US DailyMed: Polatuzumab vedotin;
Pregnancy; category	AU: D;
ATC code	L01FX14 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only / Schedule D; UK: POM (Prescription only); US: ℞-only; EU: Rx-only; In general: ℞ (Prescription only);
Identifiers
CAS Number	1313206-42-6;
IUPHAR/BPS	8404;
DrugBank	DB12240;
ChemSpider	none;
UNII	KG6VO684Z6;
KEGG	D10761;
Chemical and physical data
Formula	C6670H10317N1745O2087S40
Molar mass	149627.43 g·mol−1

Polatuzumab vedotin, sold under the brand name Polivy, is a CD79b-directed antibody-drug conjugate medication used for the treatment of diffuse large B-cell lymphoma (cancer). It was developed by the Genentech subsidiary of Roche.

The most common side effects include low levels of white blood cells (neutropenia), platelets (thrombocytopenia) and red blood cells (anemia); nerve damage (peripheral neuropathy); fatigue; diarrhea; fever; decreased appetite; and pneumonia.

Polatuzumab vedotin was approved for medical use in the United States in June 2019, in Australia in October 2019, in the European Union in January 2020, and in Canada in November 2020.